Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Oromandibular dyskinesia"
Filter
Filter
Article category
Keywords
Publication year
Authors
Case Report
Oromandibular Dyskinesia as the Initial Manifestation of Late-Onset Huntington Disease
Dong-Seok Oh, Eun-Seon Park, Seong-Min Choi, Byeong-Chae Kim, Myeong-Kyu Kim, Ki-Hyun Cho
J Mov Disord. 2011;4(2):75-77.
DOI: https://doi.org/10.14802/jmd.11016
  • 60,868 View
  • 61 Download
  • 4 Citations
AbstractAbstract PDF

Huntington’s disease (HD) is a neurodegenerative disorder characterized by a triad of choreoathetosis, dementia and dominant inheritance. The cause of HD is an expansion of CAG trinucleotide repeats in the HD gene. Typical age at onset of symptoms is in the 40s, but the disorder can manifest at any time. Late-onset (≥ 60 years) HD is clinically different from other adult or juvenile onset HD and characterized by mild motor problem as the initial symptoms, shorter disease duration, frequent lack of family history, and relatively low CAG repeats expansion. We report a case of an 80-year-old female with oromandibular dyskinesia as an initial manifestation of HD and 40 CAG repeats.

Citations

Citations to this article as recorded by  
  • Harmine prevents 3-nitropropionic acid-induced neurotoxicity in rats via enhancing NRF2-mediated signaling: Involvement of p21 and AMPK
    Mohamed Z. Habib, Mariane G. Tadros, Hadwa A. Abd-Alkhalek, Magda I. Mohamad, Dalia M. Eid, Fatma E. Hassan, Hend Elhelaly, Yasser el Faramawy, Sawsan Aboul-Fotouh
    European Journal of Pharmacology.2022; 927: 175046.     CrossRef
  • Orofacial Dyskinesia and Intractable Hiccups in a Patient with Varicella-Zoster Virus Encephalomyelitis
    Akito Funatsu, Yohei Yamamoto, Midori Araki, Fumitoshi Aga, Hideki Mine
    Internal Medicine.2022;[Epub]     CrossRef
  • Management of Traumatic Ulcerations of Lips in a Case of Huntington’s Disease: A Novel Application of Essix Retainer
    Mohamed Iqbal J
    Journal of Indian Orthodontic Society.2021; 55(4): 415.     CrossRef
  • The oral manifestations of Huntington's disease: A systematic review of prevalence
    Luciana Munhoz, Ashjan Qasim Jabbar, William José e Silva Filho, Aline Yukari Nagai, Emiko Saito Arita
    Oral Diseases.2021;[Epub]     CrossRef
Original Article
Anticholinergic Agents Can Induce Oromandibular Dyskinesia
Hee-Young Shin, Won Tae Yoon, Won Yong Lee
J Mov Disord. 2009;2(2):69-71.
DOI: https://doi.org/10.14802/jmd.09018
  • 17,248 View
  • 70 Download
  • 2 Citations
AbstractAbstract PDF
Background and Purpose:

Oromandibular dyskinesia (OMD) can occur spontaneously or they can be induced by the conventional dopamine receptor antagonists. Anticholinergic medications have rarely been reported to cause OMD in parkinsonian or non-parkinsonian patients.

Methods:

We analyzed the clinical features of two parkinsonian and one non-parkinsonian patients who experienced OMD after anticholinergic medication.

Results:

Each patient of our cases developed oromandibular symptoms in the temporal regions that were related to the addition of anticholinergic agents, and the symptoms were relieved following the discontinuation of the causative anticholinergic drugs. In one of our case, levodopa alone did not cause dyskinesia but augmented dyskinesia associated with anticholinergics.

Conclusions:

Here we report two parkinsonian and one non-parkinsonian patients with OMD induced by the use of anticholinergic agents. In our cases, we could not find any other precipitating or actual secondary causes for the OMD symptoms in our patients. Furthermore, the fact that the OMD in our cases were ameliorated with cessation of anticholinergics suggests that it may be anticholinergic-induced.

Citations

Citations to this article as recorded by  
  • Impact of anticholinergic drugs withdrawal on motor function in patients with Parkinson’s disease
    Yasaman Saeedi, Maryam Ghadimi, Mohammad Rohani, Maziar Emamikhah, Gholamali Shahidi, Mehdi Moghaddasi, Seyed Amir Hassan Habibi
    Clinical Neurology and Neurosurgery.2021; 202: 106480.     CrossRef
  • Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors
    Nicki Niemann, Joseph Jankovic
    Drugs.2018; 78(5): 525.     CrossRef

JMD : Journal of Movement Disorders